Multi-targeted approach in the treatment of thyroid cancer

Figures & data

Table 1 National Cancer Institute/US National Institutes of Health list of clinical trials now accepting participants

Clinical trial title	Phase	Type	Status	Age	Sponsor
1. Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer	II	Treatment	Active	16 and over	NIDDK
2. Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors	III	Treatment	Active	18 and over	Other
3. Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)	II	Treatment	Active	18 and over	Other
4. Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma	II	Treatment	Active	18 and over	Other
5. An Initial Study of Lithium in Patients With Medullary Thyroid Cancer	NS	Treatment	Active	18 and over	Other
6. Thyroid Cancer and Sunitinib	II	Treatment	Active	18 and over	Other
7. Phase 2 Study Of AG-013736 In Patients With Doxorubicin-Refractory Or Intolerant Thyroid Cancer	II	Treatment	Active	18 and over	Pharmaceutical/Industry
8. Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours	II	Treatment	Active	18 and over	Pharmaceutical/Industry
9. Phase II Two-Step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma	II	Treatment	Active	18 to 75	Other
10. A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors	I	Treatment	Active	18 and over	Pharmaceutical/Industry
11. Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer	II	Treatment	Active	18 and over	NCI
12. Lithium for Low-Grade Neuroendocrine Tumors	II	Treatment	Active	18 and over	NCI, Other
13. The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors	II	Treatment	Active	18 and over	Other
14. A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer	I, II	Treatment	Active	18 and over	Pharmaceutical/Industry
15. Efficacy and Safety of Zactima^™ in Patients With Metastatic Papillary or Follicular Thyroid Cancer	II	Treatment	Active	18 and over	Pharmaceutical/Industry
16. Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases	I	Treatment	Active	18 and over	Other
17. Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer	II	Treatment	Active	18 and over	NCI
18. 17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer	II	Treatment	Active	18 and over	NCI
19. Pazopanib in Treating Patients With Advanced Thyroid Cancer	II	Biomarker/Laboratory Analysis, Treatment	Active	18 and over	NCI
20. AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine	II	Biomarker/Laboratory Analysis, Treatment	Active	18 and over	NCI
21. FR901228 in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine	II	Treatment	Active	18 and over	NCI
22. FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer	I	Treatment	Active	18 and over	NCI
23. Vandetanib in Treating Young Patients With Medullary Thyroid Cancer	II	Biomarker/Laboratory Analysis, Treatment	Active	5 to 18	NCI
24. Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer	II	Biomarker/Laboratory Analysis, Treatment	Active	18 and over	NCI
25. Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer	III	Treatment	Active	18 and over	Pharmaceutical/Industry
26. Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors	II	Treatment	Active	18 and over	Other
27. Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery	II	Treatment	Active	18 and over	NCI
28. Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer	II	Treatment	Active	18 and over	Pharmaceutical/Industry, NCI
29. Lenalidomide in Treating Patients With Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine and Cannot Be Removed By Surgery	II	Biomarker/Laboratory Analysis, Treatment	Active	18 and over	Pharmaceutical/Industry, Other
30. Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma	II	Treatment	Active	18 and over	Other
31. Sorafenib in Treating Patients With Metastatic or Unresectable Resistant Thyroid Cancer	II	Biomarker/Laboratory Analysis, Treatment	Active	NS	NCI
32. Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer	II	Treatment	Active	18 and over	NCI, Other

Abbreviations: NS, not specified; NCI, national cancer institute; NIDDK, national institute of diabetes and digestive and kidney diseases.